Xcout Intel
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Subscribe to see Tarsus Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Tarsus Pharmaceuticals, Inc. at a glance
Tarsus Pharmaceuticals, Inc. is a biotechnology company headquartered in Irvine, United States. It is publicly listed (TARS) with a market capitalisation of $3.1B. Xcout tracks 18 named people at Tarsus Pharmaceuticals, Inc., including Seshadri Neervannan (Chief Operating Officer). Xcout recorded 39 job postings from Tarsus Pharmaceuticals, Inc. in the last 90 days.
Tarsus Pharmaceuticals, Inc. leadership
- Seshadri NeervannanChief Operating Officer
- Jeffrey S FarrowChief Financial Officer & Chief Strategy Officer
- Dianne C. WhitfieldChief Human Resources Officer
- Elizabeth YeuChief Medical Officer
- Bobak R. AzamianCo-Founder, President, Chief Executive Officer & Chairman
- Adrienne KempVice President of Corporate Communications
12 more named people on record for Tarsus Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Tarsus Pharmaceuticals, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $60M | 6 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Tarsus Pharmaceuticals, Inc.
Xcout recorded 39 job postings from Tarsus Pharmaceuticals, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Tarsus Pharmaceuticals, Inc.'s hiring signals →
Investors
Tech stack
Tarsus Pharmaceuticals, Inc. competitors
A few of Tarsus Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
Tarsier Pharma Ltd. is a late clinical-stage pharmaceutical company that develops bio-inspired medical solutions for autoimmune and inflammatory ocular diseases. The company utilizes a proprietary molecule-derived technology platform to target conditions such as non-infectious uveitis and uveitic glaucoma through eye drops and intravitreal injections.
LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its operations are primarily concentrated in China and the broader Asian region. The company's pipeline features several promising drug candidates targeting a range of severe illnesses. These include mavacamten, aimed at both obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction. TP-03 is being developed for Demodex blepharitis and meibomian gland dysfunction. For cancer, LianBio is advancing NBTXR3 for head and neck squamous cell carcinoma and other solid tumors, alongside Infigratinib for cholangiocarcinoma (both first-line and second-line settings) and gastric cancers, and BBP-398 also for solid tumors. Furthermore, Omilancor and NX-13 are in development for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Other programs include LYR-210 for chronic rhinosinusitis and Sisunatovir to combat respiratory syncytial virus. LianBio has established key collaborations, partnering with Tarsus Pharmaceuticals, Inc. on the development and market introduction of TP-03 specifically for Demodex blepharitis. Additionally, it maintains a strategic alliance with Nanobiotix S.A. for NBTXR3, a novel radioenhancer intended for direct intratumoral injection before conventional radiation therapy. Established in 2019, the company's corporate headquarters are located in Princeton, New Jersey.
Aperta Biosciences is a biopharmaceutical company that develops novel therapeutics for ocular surface diseases, including blepharitis, ocular rosacea, meibomian gland dysfunction, and dry eye disease. The company's lead candidate, APT-001, is an ophthalmic suspension designed to treat the underlying cause of blepharitis by eradicating ocular Demodex infestations.
Tavo Biotherapeutics is a biotechnology company headquartered in Laguna Beach, California. The company focuses on driving breakthrough pharmaceutical innovations and developing novel treatments for glaucoma and vision preservation.
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Get Tarsus Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Tarsus Pharmaceuticals, Inc. in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 1 funding round before the IPO with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access